Village Farms is a newly focused, profitable cannabis export platform trading at distressed multiples despite EU-GMP scale, German medical momentum, and asymmetric five-year upside.
Village Farms International, Inc. (VFF) operates as a vertically integrated global cannabis platform, having completed a structural transformation from a legacy agricultural business to a pure-play, high-margin consumer packaged goods (CPG) operator.[1, 2] On May 30, 2025, the company finalized a joint venture agreement with Vanguard Food LP (now Verdexa Holdings), backed by private equity firms Sweat Equities, LLC and Kennedy Lewis Investment Management.[3, 4] Through this transaction, Village Farms privatized the majority of its legacy produce business, divesting 80 acres of Texas greenhouse assets in exchange for $40.0 million in cash and a 37.9% initial equity stake in Verdexa.[2, 3] Consequently, the company has removed consolidated exposure to agricultural commodity volatility, redeploying its resources into high-growth, regulated cannabis markets.[1, 2, 5]
The company's revenue model is anchored by its newly consolidated Cannabis segment, which encompasses Canadian adult-use and wholesale operations, European medical exports, and a recreation-focused operation in the Netherlands.[1, 6] A minor U.S. CBD wellness brand, CBDistillery, operates through direct-to-consumer online channels, though it represents a shrinking portion of overall revenues.[7, 8, 9] Geographically, Canada serves as the primary cash-generating hub, from which the company leverages its scale to export high-margin, European Union Good Manufacturing Practice (EU-GMP) certified flower to expanding international medical markets.[1, 5, 8]
| Operational Attribute | Consolidated Detail |
|---|---|
| Core Products | Dried flower formats, automated pre-rolls, cured resin vapes, and hemp-derived CBD wellness products.[7, 8, 10, 11] |
| Primary Customers | Canadian provincial retail distribution boards, European clinical pharmaceutical distributors, and direct-to-consumer CBD purchasers.[1, 8, 9] |
| Important End Markets | Canadian adult-use retail, German and United Kingdom medical channels, and the Dutch regulated recreational pilot program.[1, 8, 12] |
| Value Proposition | Low-cost cost structure, reliable quality consistency, and clinical-grade EU-GMP compliance at industrial scale.[1, 5, 8] |
Customers select Village Farms over alternatives due to its structural cost advantage and clinical-grade compliance. In the saturated Canadian retail market, consumers favor its Pure Sunfarms and Fraser Valley brands for consistent potency and attractive pricing made possible by large-scale greenhouse cultivation.[8, 11] In international medical markets, clinical distributors and pharmacies choose Village Farms because it operates what it believes to be the world's largest EU-GMP certified cannabis cultivation campus.[1, 8] This certification guarantees strict microbial compliance and standardized chemical profiles, insulating the company's export pricing from the severe compression observed in non-certified, lower-tier wholesale biomass markets.[5, 13] TRANSFORMATIONAL PURSUIT OF VALUE.
The economics of the global cannabis enterprise are driven by greenhouse operating leverage, geographic expansion, and high barriers to entry.
Village Farms cultivates, processes, and packages a diversified portfolio of dried flower, pre-rolls, vapes, and extracts.[7, 8, 10, 11] In Canada, its operations are executed via its wholly-owned Pure Sunfarms subsidiary in British Columbia and its 80%-owned Rose LifeScience partner in Quebec.[1, 8, 14] Brand tiers target specific consumer segments:
* Fraser Valley Weed Co.: High-volume, budget-conscious consumers purchasing large-format dried flower packages.[7, 11]
* Pure Sunfarms: Mid-market consumer segments, driven by flagship cultivars such as Pink Kush, one of the most widely consumed strains globally.[8]
* Super Toast and Soar: Premium whole-flower and pre-shred formats targeting high-potency and artisanal consumer demands respectively.[7, 11]
* Rose LifeScience (Promenade, Tam Tams): Locally tailored heritage brands capturing high retail market share in the Quebec region.[7, 14]
The product portfolio has expanded into vapes and concentrates, including the Pure Sunfarms Pink Kush Cured Resin 510 Vape, designed to capture share in the higher-margin extraction category.[10] In the United States, its CBDistillery brand produces and sells CBD softgels, sleep-targeted gummies, and targeted topicals directly to consumers.[7, 8, 9]
The company's competitive advantage is defined by its Controlled Environment Agriculture (CEA) scale and regulatory compliance.
────►
│
▼
◄────
Village Farms possesses over three decades of CEA greenhouse operating experience, allowing it to cultivate at a lower cash cost per gram compared to competitors using indoor warehouse setups.[8] Its 7.0 million square foot global greenhouse footprint utilizes automated packaging and optimized natural light to maintain consistent yields while absorbing fixed overhead costs.[7, 8]
This cost advantage is reinforced by its EU-GMP certification, which acts as a regulatory barrier to entry.[1] Achieving EU-GMP status at its massive Delta, British Columbia cultivation campus required significant capital expenditures and complex standard operating procedures to meet strict European pharmaceutical standards.[1, 8, 13] This certification enables Village Farms to export medical cannabis directly into European markets, shielding its margins from the oversupplied domestic Canadian wholesale market.[1, 5, 13]
In the Netherlands, Leli Holland holds one of only ten licenses in the country’s closed recreational supply chain pilot program.[7, 8] This creates a localized regulatory oligopoly, granting the company exclusive access to supply adult-use coffee shops in participating municipalities.[2, 8]
The primary growth driver for Village Farms is the progressive deregulation of European medical and adult-use cannabis.[1, 2] In Germany, the implementation of the Cannabis Act (CanG) in April 2024 removed cannabis from the narcotics list, eliminating complex administrative burdens for doctors, wholesalers, and pharmacies.[13, 15] This reform expanded the German medical import market, with total imports nearly tripling from 72.9 tonnes in 2024 to 201.1 tonnes in 2025.[16] Germany’s pharmacy sell-out market surpassed €1.0 billion in 2025, and industry analysts project the German regulated medical market could grow to over €4.5 billion by 2028.[16] Longer term, the broader European medical market is modeled at over €20.0 billion annually, positioning Germany as the central pharmaceutical distribution hub.[17]
In European export channels, Village Farms competes with established Canadian operators, including Curaleaf, Organigram, Canopy Growth, and Tilray.[16] Curaleaf (through its €100 million revenue Four20 Pharma subsidiary) and Organigram (via its avaay medical brand) currently lead in German pharmacy market share.[16] However, Village Farms is capturing ground.[1, 5] Through its specialized local distribution partners, the company has secured three of the top five leading cultivars and four of the top ten overall cultivars in Germany, with its pricing holding steady due to the distinct quality of its EU-GMP certified flower.[1, 5] In Canada, despite intense retail fragmentation and severe price compression, Village Farms holds a top-three overall national market share and remains the leader in dried flower formats.[12, 18] DOMINANT OPERATIONAL SCALE.
Village Farms reported its first quarter 2026 financial results on May 11, 2026, showcasing a strong turnaround in profitability.[1, 19]
| Financial Metric | Q1 2026 Reported [1] | Q1 2025 Reported [1] | Year-over-Year Change (%) |
|---|---|---|---|
| Consolidated Net Sales | $50.24 million | $39.68 million | +26.6% |
| GAAP Net Income (Loss) | $2.92 million | ($6.70 million) | Turnaround to Profit |
| Diluted Earnings Per Share | $0.02 | ($0.06) | Turnaround to Profit |
| Consolidated Gross Profit | $20.99 million | $14.18 million | +48.0% |
| Adjusted EBITDA | $9.89 million | $4.55 million | +117.5% |
| Cash and Cash Equivalents | $55.53 million | $15.13 million | +267.0% [9, 20] |
Consolidated revenues of $50.24 million beat Wall Street consensus expectations of $47.81 million to $48.29 million by approximately 4.5%, driven by international medical exports.[19, 21] Diluted GAAP EPS of $0.02 met consensus expectations, marking the company’s fourth consecutive quarter of positive consolidated net income.[5, 19, 22]
The Cannabis segment generated external sales of $49.74 million and operating income of $6.49 million, offset by cost of sales of $28.44 million and SG&A expenses of $14.82 million.[6] This segment’s gross margin improved to 43.0%, surpassing management's long-term target range of 30.0% to 40.0%.[1] This performance was driven by international medical exports, which rose 171.0% year-over-year and 60.0% sequentially to a record $14.58 million, accounting for 29.3% of total Cannabis segment revenue.[1, 9] The legacy produce and non-core energy operations, reported under the "Other" segment, registered external sales of $494,000 and an operating loss of $834,000.[6]
Operating cash flow for the quarter was negative $11.81 million, down from positive $2.89 million in Q1 2025.[1] This outflow was driven by a $15.0 million cash tax payment in Canada for liabilities accrued during the profitable 2025 fiscal year.[1, 23] Management noted that all historical tax loss carryforwards were fully utilized in 2025, requiring cash tax payments for the first time.[23] Normalized cash flow from operations, excluding this non-recurring payment, remained positive, and management expects cash balances to grow organically through the remainder of 2026.[1, 24]
On the Q1 2026 earnings call, Chief Executive Officer Michael DeGiglio emphasized that the international medical export business remains the primary driver of both top-line growth and margin expansion.[5] Management provided forward guidance with quarterly EPS projections ranging from $0.03 to $0.05.[22] Following the results, consensus estimates for full-year 2026 revenue were upgraded to $242.9 million, though full-year consensus EPS was adjusted to $0.143 to account for capital allocation shifts and short-term capacity constraints ahead of greenhouse expansions.[25]
Following the earnings release, the stock initially rose 3.89% in pre-market trading, reflecting investor confidence in the positive net income trajectory.[22] However, on June 5, 2026, the company announced a registered direct equity offering of 7,500,000 common shares at a negotiated price of $2.00 per share to institutional investors.[24, 26] This placement, managed by sole agent A.G.P./Alliance Global Partners, raised $15.0 million in gross proceeds ($13.9 million net after a 5.5% cash fee of $825,000 and other expenses).[26] This dilutive event increased the total shares outstanding by 6.6% to 121,811,130, causing the stock to drop 14.0% on the day of the announcement and close at $1.85.[26, 27, 28]
At the current share price of $1.86, valuation metrics remain highly compressed:
* Trailing Price-to-Earnings (P/E) Ratio: 5.06x to 5.11x.[29, 30]
* Price-to-Sales (P/S) Ratio: 1.00x.[30]
* Enterprise Value-to-EBITDA (EV/EBITDA) TTM: 4.54x.[30]
* Price-to-Book (P/B) Ratio: 0.72x.[30]
The core driver for long-term valuation is the 5-year sales growth CAGR. While the company's historical 5-year consolidated sales growth CAGR was limited to 3.54% due to the divestment of its legacy fresh produce operations, forward-looking sales growth is projected to grow at an 11.5% to 17.5% CAGR through 2031.[2, 27, 31, 32] This top-line growth, combined with the 43.0% gross margin profile of international medical exports, is expected to drive meaningful cash flow and valuation multiple expansion as international markets continue to deregulate.[1, 30] ATTRACTIVE VALUATION DISCONNECT.
As Village Farms transitions to a pure-play cannabis operator, its risk profile has shifted from agricultural weather exposure to complex regulatory and execution dynamics.
The company is managing two concurrent, capital-intensive cultivation expansions.[1, 23] In Canada, it is planting the second half of its Delta 2 (D-2) greenhouse expansion, designed to add an incremental 40 metric tonnes of annualized capacity (a 33.0% increase in BC output) by mid-2027.[1, 10] In the Netherlands, Phase II Groningen expansion is designed to quintuple local capacity to approximately 10 metric tonnes annually by early 2027.[1, 8]
If these facilities experience biosecurity issues, crop disease, or HVAC failures, the resulting under-absorption of fixed overhead would compress segment margins.[7, 12] Furthermore, management's decision in June 2026 to accelerate D-2 technology upgrades into Q4 2026—ahead of the original 2027 schedule—poses risks of short-term planting disruptions, although it was executed in response to strong demand.[10, 33]
The Canadian recreational market remains highly fragmented and competitive, with flat retail sales and persistent wholesale price compression forcing operators into low-margin value tiers.[11, 23, 34] While export margins to Germany remain high, a rapid influx of low-cost imported flower from emerging low-cost jurisdictions could trigger a structural price decline, narrowing the high margins currently generated on exports.[5, 17]
This competitive headwind is compounded by the Canadian flat-rate excise tax structure, which consumes nearly 40.0% of retail branded cannabis sales and acts as a drag on domestic profitability.[9]
The rapid expansion of the German medical market (~900,000 patients in mid-2025, up from ~250,000 pre-CanG) was largely enabled by the growth of online telemedicine prescribing platforms.[13, 16] If German regulators restrict telemedicine access or impose strict in-person consultation requirements, patient acquisition will slow, directly impacting medical export volumes.[16]
Furthermore, the company relies on a small group of German pharmaceutical distribution partners; any operational disruption or contract termination with these distributors would impact market access.[1, 5]
The U.S. CBD segment (CBDistillery) remains under pressure, with revenues declining 20.0% to $3.13 million in Q1 2026 due to competition from unregulated synthetic hemp-derived products (such as delta-8 THC) and the lack of a clear FDA regulatory pathway for ingestible cannabinoids.[9] If federal regulators ban hemp-derived cannabinoids or fail to establish a standard framework, the carrying value of this segment's goodwill may require impairment.
The company carries long-term debt, including a variable-rate Farm Credit Canada (FCC) loan with a balance of $15.4 million, leaving it exposed to interest rate hikes under SOFR and CORRA frameworks.[1, 6, 35] Additionally, the recent $15.0 million registered direct offering in June 2026 highlights the risk of equity dilution, even when cash on hand is sufficient.[14, 24]
The risk landscape can be structured by urgency and potential impact on the long-term investment thesis:
[Operational Issues] ─────────────────► ──────► [European Price Collapse]
(Under-absorption / delays) (Slowing patient growth) (Loss of high-margin mix)
*Low Impact / Near Term* *Medium Impact / Mid Term* *High Impact / Long Term*
The 5-year valuation projections for Village Farms are based on a current share price of $1.86 as of June 26, 2026, with a post-offering share count of 121,811,130.[24, 30]
The Base Case assumes the German medical market continues to expand steadily, and the company successfully completes and ramps up its D-2 and Groningen Phase II expansions by early 2027.[1, 10]
* Revenue Projection: Top-line revenue grows at an 11.5% CAGR, reaching $380.00 million by Year 5 (2031).[32] This is driven by international medical export sales reaching $80.00 million annually and the Netherlands pilot program achieving steady-state operations.
* Margins & Earnings: Cannabis segment gross margins stabilize at 40.0%, supported by a high-margin export mix.[1] SG&A expenses benefit from operating leverage, decreasing to 18.0% of sales.[23] This drives an EBITDA margin of 19.0%, generating Year 5 EBITDA of $72.20 million.[27]
* Share Count & Multiple: Minor annual dilution from stock-based compensation increases the diluted share count to 130.00 million. The company is valued at an EV/EBITDA exit multiple of 7.5x, reflecting its stable, profitable CPG model.[27, 30]
* Valuation Bridge:
$\text{Implied Enterprise Value} = \$72.20\text{M} \times 7.5 = \$541.50\text{M}$
Subtracting debt and adding accumulated cash yields an estimated Year 5 Net Cash position of $30.00 million, resulting in an Implied Equity Value of $571.50 million.
$\text{Implied Share Price} = \frac{\$571.50\text{M}}{130.00\text{M shares}} = \$4.40\text{ USD}$
This represents a 5-year total return of 136.6%, or an 18.8% annualized return.
The High Case assumes a highly favorable regulatory environment, characterized by full adult-use legalization in Germany, rapid expansion of medical programs across Europe, and the rescheduling of cannabis to Schedule III in the United States, which removes 280E tax penalties.[28]
* Revenue Projection: Revenues grow at a 17.5% CAGR, reaching $550.00 million by Year 5, driven by international medical exports and a full-scale recreational rollout in European markets.[32]
* Margins & Earnings: High-margin formats make up a larger portion of sales, expanding the EBITDA margin to 25.0%, resulting in Year 5 EBITDA of $137.50 million.[10, 23]
* Share Count & Multiple: Diluted share count increases to 135.00 million. The company's exit EV/EBITDA multiple expands to 10.0x, in line with high-growth consumer brands.[27, 32]
* Valuation Bridge:
$\text{Implied Enterprise Value} = \$137.50\text{M} \times 10.0 = \$1,375.00\text{M}$
Strong cash flows allow the company to build a Net Cash position of $80.00 million, leading to an Implied Equity Value of $1,455.00 million.
$\text{Implied Share Price} = \frac{\$1,455.00\text{M}}{135.00\text{M shares}} = \$10.78\text{ USD}$
This represents a 5-year total return of 479.6%, or a 42.1% annualized return.
The Low Case assumes severe pricing compression in both the European medical and Canadian recreational markets, combined with persistent execution delays in the Delta 2 and Groningen facilities.[17, 34]
* Revenue Projection: Revenue remains flat, ending Year 5 at $220.00 million, as declines in U.S. CBD and Canadian wholesale offset minor export gains.[9, 31]
* Margins & Earnings: Margin compression and higher Canadian excise taxes reduce the EBITDA margin to 8.0%, leading to Year 5 EBITDA of $17.60 million.[9, 23]
* Share Count & Multiple: Capital constraints force the company to issue more dilutive equity, raising the share count to 140.00 million.[24] The EV/EBITDA exit multiple contracts to a conservative 4.0x.[30]
* Valuation Bridge:
$\text{Implied Enterprise Value} = \$17.60\text{M} \times 4.0 = \$70.40\text{M}$
Ongoing cash burn leaves the company with a Net Debt position of $20.00 million, reducing the Implied Equity Value to $50.40 million.
$\text{Implied Share Price} = \frac{\$50.40\text{M}}{140.00\text{M shares}} = \$0.36\text{ USD}$
This represents a 5-year total loss of 80.6%, or a -28.2% annualized return.
| Scenario | Year 1 (2027) | Year 2 (2028) | Year 3 (2029) | Year 4 (2030) | Year 5 (2031) |
|---|---|---|---|---|---|
| High Case | $2.50 | $3.60 | $5.10 | $7.40 | $10.78 |
| Base Case | $2.10 | $2.50 | $3.00 | $3.60 | $4.40 |
| Low Case | $1.40 | $1.00 | $0.70 | $0.50 | $0.36 |
| Scenario | Year 5 Revenue (USD) | EBITDA Margin Assumption | Exit Multiple (EV/EBITDA) | Current Price (USD) | Implied Year 5 Price (USD) | 5-Year Return (%) | Annualized Return (%) | Probability Weight |
|---|---|---|---|---|---|---|---|---|
| High Case | $550 million | 25.0% | 10.0x | $1.86 | $10.78 | +479.6% | +42.1% | 20% |
| Base Case | $380 million | 19.0% | 7.5x | $1.86 | $4.40 | +136.6% | +18.8% | 60% |
| Low Case | $220 million | 8.0% | 4.0x | $1.86 | $0.36 | -80.6% | -28.2% | 20% |
| Weighted Target | — | — | — | $1.86 | $4.87 | +161.8% | +21.2% | 100% |
The probability-weighted target price of $4.87 USD suggests an asymmetric risk-reward profile, where the growth of the European medical business offsets domestic Canadian market risks.[1, 27] ASYMMETRIC RETURN PROFILE.
This qualitative evaluation assesses the fundamental durability and execution capabilities of Village Farms.
| Evaluation Category | Score (1-10) | Primary Qualitative Drivers and Narrative |
|---|---|---|
| Management Alignment | 8 / 10 | Founder and CEO Michael DeGiglio has led the company since its inception in 1989.[36] DeGiglio directly owns 9,622,441 shares (~8.45% of the pre-offering equity), representing approximately $17.8 million in personal capital exposed to company performance.[36, 37] However, executive compensation is relatively high, with DeGiglio's total annual compensation at $3.78 million, which sits above the average for peers of similar market capitalization.[36] |
| Revenue Quality | 7 / 10 | The privatization of the legacy produce assets removes low-margin agricultural volatility.[2, 3] High exposure to international exports (Germany) provides high-margin revenue stream.[1] However, Canadian revenues remain subject to flat retail trends, and the U.S. CBD business is under pressure from unregulated synthetic hemp competition.[8, 9] |
| Market Position | 8 / 10 | Village Farms maintains a top-three brand position in Canada, leads in dried flower, and is one of only ten licensed producers in the Dutch pilot program.[7, 8, 12] It is also a leading exporter of medical cannabis to Germany, with three of the top five cultivars.[1, 5] |
| Growth Outlook | 8 / 10 | Growth is driven by European medical market expansion and Groningen Phase II in the Netherlands.[2, 7, 13] Top-line growth is supported by the Delta 2 expansion in Canada, which will add 40 metric tonnes of annual capacity by mid-2027.[1, 10] |
| Financial Health | 7 / 10 | Low leverage with a debt-to-equity ratio of 0.14x and a current ratio of 3.06x.[29, 30] At the end of Q1 2026, it held $55.53 million in cash against approximately $40.0 million in total debt.[9, 38] However, cash flow remains sensitive to tax liabilities and capital expenditure demands.[1, 39] |
| Business Viability | 8 / 10 | By transitioning to a pure-play cannabis model and securing EU-GMP certified infrastructure, Village Farms has established a sustainable operating model.[1, 3, 8] The main bottleneck remains the Canadian excise tax structure, which consumes nearly 40.0% of retail branded revenues, making international expansion critical to its long-term viability.[9] |
| Capital Allocation | 6 / 10 | Management has demonstrated a mixed track record. While the completion of its $10.0 million share repurchase program in early 2026 was a positive step, the decision to raise $15.0 million through a dilutive direct offering at $2.00 per share in June 2026—only weeks after buying back shares—indicates some inconsistency in capital execution.[24, 25, 40] |
| Analyst Sentiment | 5 / 10 | Wall Street sentiment is divided. Some consensus platforms rate the stock as a "Reduce," pointing to recent equity dilution and flat retail trends in Canada.[23, 41] Conversely, boutique cannabis and consumer-staples analysts maintain highly bullish views, with price targets ranging from $4.25 to $5.50, implying substantial upside from current levels.[18] |
| Profitability | 7 / 10 | Profitability has improved, driven by higher-margin medical exports and solid execution in its Canadian segment.[1, 22] Q1 2026 marked its fourth consecutive quarter of positive net income, with a cannabis gross margin of 43.0%.[1, 5] |
| Track Record | 5 / 10 | While the team has proven to be an exceptional greenhouse operator, historical long-term shareholder value creation has been weak.[8, 38] Over the past five years, the stock has lost approximately 82.0% of its value, driven by the broader cannabis sector downturn and legacy produce struggles, although the business has now been fundamentally restructured.[3, 30, 38] |
This blended score reflects a company with strong operational scale and regulatory advantages, but one that continues to navigate a challenging industry landscape and inconsistent capital allocation decisions. STRENGTH WITH DILUTION RISK.
Village Farms represents a compelling transition story in the global cannabis industry. By divesting the majority of its low-margin agricultural produce business, the company has transformed into a pure-play, profitable global cannabis operator with a solid margin profile.[1, 2, 3]
The core investment thesis is built on three key pillars:
1. Cost and Scale Leadership: Decades of greenhouse operational experience and the world's largest EU-GMP certified cultivation campus provide a low-cost, compliant product supply that is difficult to replicate.[1, 8]
2. European Regulatory Positioning: The removal of narcotics classification in Germany has accelerated medical demand.[13] Village Farms is capitalizing on this through its established medical export channels, where it holds a leading position in pharmacy distribution.[1, 5] Additionally, its participation in the Dutch recreational pilot program offers protected growth potential.[7, 8]
3. Turnaround in Fundamentals: Achieving positive GAAP net income for four consecutive quarters highlights that the business model is self-sustaining, reducing its reliance on dilutive capital raises compared to its peers.[1, 5, 42]
The primary risk to this thesis is the potential for pricing compression to spread from Canada to European export channels as global supply chains mature, alongside execution risks in scaling its Delta 2 and Groningen facilities.[10, 17, 34] Additionally, the recent $15.0 million equity raise in June 2026 indicates that management may prioritize capital accumulation over near-term share price preservation, presenting a risk of further dilution.[24, 28]
Nevertheless, at a trailing P/E of 5.06x and an EV/EBITDA of 4.54x, the company is trading at valuations that do not reflect its profitable pure-play position or its growth exposure in Europe.[29, 30] The probability-weighted scenario analysis suggests that the stock is undervalued, with a potential price target of $4.87 USD over the next five years.[27] TRANSFORMED CANNABIS ENGINE.
Village Farms is in a clear medium-term downtrend, trading at $1.86 as of late June 2026.[27, 30] The stock is trading significantly below its simple 200-day moving average, which is currently sitting between $2.2552 and $3.0849 depending on the metric provider.[43, 44] The short-term price action has been dominated by technical selling following the June 5, 2026 announcement of the registered direct offering of 7.5 million shares at $2.00, which created an immediate overhang of diluted supply.[24, 26, 28] While extremely oversold indicators (including an RSI of 23.65) suggest a potential technical bounce, the short-term outlook remains bearish until the stock can consolidate and reclaim support above its key short-term moving averages.[30] BEARISH PRICE CONSOLIDATION.
View Village Farms International, In (VFF) stock page
Loading the interactive version of this report…